Ascendis Pharma A/S (NASDAQ:ASND) SVP Mads Bodenhoff Sells 3,000 Shares

Ascendis Pharma A/S (NASDAQ:ASND) SVP Mads Bodenhoff sold 3,000 shares of Ascendis Pharma A/S stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $270.19, for a total transaction of $810,570.00. Following the sale, the senior vice president owned 3,000 shares of the company’s stock, valued at approximately $810,570. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Ascendis Pharma A/S Trading Down 3.4%

Shares of Ascendis Pharma A/S stock traded down $9.28 on Wednesday, reaching $260.81. The company had a trading volume of 476,161 shares, compared to its average volume of 674,457. The firm’s 50 day moving average price is $258.05 and its two-hundred day moving average price is $241.50. The firm has a market cap of $16.27 billion, a PE ratio of 20.23 and a beta of 0.35. Ascendis Pharma A/S has a 52-week low of $186.05 and a 52-week high of $282.15. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.32 and a current ratio of 2.99.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings data on Friday, August 14th. The biotechnology company reported $1.03 EPS for the quarter, missing the consensus estimate of $1.71 by ($0.68). The company had revenue of $387.22 million during the quarter, compared to analyst estimates of $376.75 million. Ascendis Pharma A/S had a return on equity of 32.54% and a net margin of 70.99%. Sell-side analysts predict that Ascendis Pharma A/S will post 5.15 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ASND. Advisory Services Network LLC acquired a new stake in shares of Ascendis Pharma A/S in the 3rd quarter valued at $26,000. Arax Advisory Partners grew its stake in shares of Ascendis Pharma A/S by 212.2% during the fourth quarter. Arax Advisory Partners now owns 153 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 104 shares in the last quarter. Leonteq Securities AG purchased a new position in Ascendis Pharma A/S in the fourth quarter valued at $36,000. Caitong International Asset Management Co. Ltd purchased a new position in Ascendis Pharma A/S in the fourth quarter valued at $42,000. Finally, Global Retirement Partners LLC increased its holdings in Ascendis Pharma A/S by 111.9% in the fourth quarter. Global Retirement Partners LLC now owns 214 shares of the biotechnology company’s stock valued at $46,000 after buying an additional 113 shares during the last quarter.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on ASND. UBS Group set a $345.00 target price on shares of Ascendis Pharma A/S in a research note on Monday, August 31st. Bank of America dropped their price target on shares of Ascendis Pharma A/S from $306.00 to $304.00 and set a “buy” rating for the company in a research note on Monday, August 31st. Royal Bank Of Canada upped their price objective on Ascendis Pharma A/S from $280.00 to $290.00 and gave the stock an “outperform” rating in a research report on Friday, August 14th. BMO Capital Markets initiated coverage on Ascendis Pharma A/S in a research note on Tuesday, August 18th. They issued an “outperform” rating and a $319.00 price objective on the stock. Finally, Barclays reduced their price objective on Ascendis Pharma A/S from $345.00 to $329.00 and set an “overweight” rating on the stock in a research note on Friday, August 14th. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $310.05.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.